{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T12:23:35Z","timestamp":1783427015197,"version":"3.54.6"},"reference-count":17,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T00:00:00Z","timestamp":1621900800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Ther Apher Dial"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Daprodustat is a hypoxia\u2010inducible factor\u2010prolyl hydroxylase inhibitor for the treatment of anemia of chronic kidney disease. This phase 3 study evaluated the efficacy and safety of daprodustat in an uncontrolled cohort of 56 Japanese peritoneal dialysis patients with anemia over 52\u2009weeks. Subjects received daprodustat 4\u00a0mg orally once daily for 4\u2009weeks and the dose was subsequently adjusted every 4\u2009weeks. Mean baseline hemoglobin was 10.9\u00a0g\/dL (95% CI 10.59, 11.12). Mean hemoglobin reached the target range (11.0\u201313.0\u00a0g\/dL) at week 12 and was maintained until week 52. Mean hemoglobin during weeks 40\u201352 was 12.1\u00a0g\/dL (95% CI 12.0, 12.2). The most frequent adverse events included nasopharyngitis (29%), catheter\u2010site infection (18%), peritonitis (16%), diarrhea (14%), and nausea (11%). No deaths were reported. Once\u2010daily oral daprodustat treatment was generally well tolerated and mean hemoglobin was achieved and maintained within the target range in Japanese peritoneal dialysis participants.<\/jats:p>","DOI":"10.1111\/1744-9987.13686","type":"journal-article","created":{"date-parts":[[2021,5,9]],"date-time":"2021-05-09T08:12:28Z","timestamp":1620547948000},"page":"979-987","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Efficacy and safety of daprodustat in Japanese peritoneal dialysis patients"],"prefix":"10.1111","volume":"25","author":[{"given":"Hidetoshi","family":"Kanai","sequence":"first","affiliation":[{"name":"Department of Nephrology Kokura Memorial Hospital  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaomi","family":"Nangaku","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Endocrinology The University of Tokyo, Graduate School of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiko","family":"Nagai","sequence":"additional","affiliation":[{"name":"Medicines Development GlaxoSmithKline  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6438-9906","authenticated-orcid":false,"given":"Nobuhiko","family":"Okuda","sequence":"additional","affiliation":[{"name":"Medicines Development GlaxoSmithKline  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyo","family":"Kurata","sequence":"additional","affiliation":[{"name":"Clinical Development GlaxoSmithKline  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Nagakubo","sequence":"additional","affiliation":[{"name":"Department of Biostatistics GlaxoSmithKline  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Endo","sequence":"additional","affiliation":[{"name":"Medicines Development GlaxoSmithKline  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Cobitz","sequence":"additional","affiliation":[{"name":"Clinical Sciences GlaxoSmithKline  King of Prussia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,5,25]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158765"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41100-017-0114-y"},{"key":"e_1_2_8_4_1","unstructured":"Kidney Disease Improving Global Outcomes.KDIGO Clinical Practice Guideline for Anemia of Chronic Kidney Disease.2012.https:\/\/kdigo.org\/guidelines\/anemia-in-ckd\/Accessed Feb 15 2020."},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-010-0396-7"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/1744-9987.12888"},{"key":"e_1_2_8_7_1","first-page":"179","article-title":"The truth on current peritoneal dialysis: state of the art","volume":"75","author":"Krediet RT","year":"2017","journal-title":"Neth J Med"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000113315.81448.CA"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802240552"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfy014"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014111139"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2015.11.021"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2015091009"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1159\/000454818"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.16011219"},{"key":"e_1_2_8_16_1","unstructured":"HamanoT.Efficacy and safety of daprodustat compared with epoetin beta pegol in Japanese non\u2010dialysis patients with anemia of chronic kidney disease: a 52\u2010week open\u2010label randomized controlled phase 3 trial. Paper presented at: ERA\u2010EDTA Congress; June 13\u201316 2019; Budapest Hungary"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/1744-9987.12520"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.jrn.2012.02.007"}],"container-title":["Therapeutic Apheresis and Dialysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1744-9987.13686","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1744-9987.13686","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1744-9987.13686","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T03:45:40Z","timestamp":1693194340000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1744-9987.13686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,25]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1111\/1744-9987.13686"],"URL":"https:\/\/doi.org\/10.1111\/1744-9987.13686","archive":["Portico"],"relation":{},"ISSN":["1744-9979","1744-9987"],"issn-type":[{"value":"1744-9979","type":"print"},{"value":"1744-9987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,25]]},"assertion":[{"value":"2020-12-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}